Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Adherence to practice guidelines is associated with reduced referral times for patients with ovarian cancer.

Boac BM, Xiong Y, Apte SM, Wenham RM, Shahzad MM, Munroe DG, Lancaster JM, Chon HS.

Am J Obstet Gynecol. 2018 Apr;218(4):436.e1-436.e7. doi: 10.1016/j.ajog.2018.01.015. Epub 2018 Jan 17.

PMID:
29353030
2.

Impact of Payer Constraints on Access to Genetic Testing.

Whitworth P, Beitsch P, Arnell C, Cox HC, Brown K, Kidd J, Lancaster JM.

J Oncol Pract. 2017 Jan;13(1):e47-e56. doi: 10.1200/JOP.2016.013581. Epub 2016 Oct 23.

PMID:
28084878
3.

MicroRNA MiR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog.

Xu CX, Xu M, Tan L, Yang H, Permuth-Wey J, Kruk PA, Wenham RM, Nicosia SV, Lancaster JM, Sellers TA, Cheng JQ.

J Biol Chem. 2016 Oct 21;291(43):22851. No abstract available.

4.

Complementary and Alternative Medicine Use in Individuals Presenting for Care at a Comprehensive Cancer Center.

Judson PL, Abdallah R, Xiong Y, Ebbert J, Lancaster JM.

Integr Cancer Ther. 2017 Mar;16(1):96-103. doi: 10.1177/1534735416660384. Epub 2016 Jul 21.

5.

Oncology healthcare providers' knowledge, attitudes, and practice behaviors regarding LGBT health.

Shetty G, Sanchez JA, Lancaster JM, Wilson LE, Quinn GP, Schabath MB.

Patient Educ Couns. 2016 Oct;99(10):1676-84. doi: 10.1016/j.pec.2016.05.004. Epub 2016 May 2.

6.

Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival.

Bush SH, Tollin S, Marchion DC, Xiong Y, Abbasi F, Ramirez IJ, Zgheib NB, Boac B, Judson PL, Chon HS, Wenham RM, Apte SM, Cubitt CL, Berglund AE, Havrilesky LJ, Lancaster JM.

Mol Clin Oncol. 2016 Mar;4(3):399-404. Epub 2016 Jan 7.

7.

Molecular determinants for lymph node metastasis in clinically early-stage endometrial cancer.

Bou Zgheib N, Marchion DC, Bush SH, Judson PL, Wenham RM, Apte SM, Lancaster JM, Gonzalez-Bosquet J.

Oncol Lett. 2016 Jan;11(1):323-329. Epub 2015 Nov 6.

8.

Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance.

Boac BM, Xiong Y, Marchion DC, Abbasi F, Bush SH, Ramirez IJ, Khulpateea BR, Clair McClung E, Berry AL, Bou Zgheib N, Chon HS, Shahzad MM, Judson PL, Wenham RM, Apte SM, Berglund AE, Magliocco AM, Lancaster JM.

Gynecol Oncol. 2016 Feb;140(2):259-63. doi: 10.1016/j.ygyno.2015.12.026. Epub 2015 Dec 28.

9.

Complementary and Alternative Medicine Use in Women With Gynecologic Malignancy Presenting for Care at a Comprehensive Cancer Center.

Abdallah R, Xiong Y, Lancaster JM, Judson PL.

Int J Gynecol Cancer. 2015 Nov;25(9):1724-30. doi: 10.1097/IGC.0000000000000549.

PMID:
26397156
10.

STAT3 polymorphisms may predict an unfavorable response to first-line platinum-based therapy for women with advanced serous epithelial ovarian cancer.

Permuth-Wey J, Fulp WJ, Reid BM, Chen Z, Georgeades C, Cheng JQ, Magliocco A, Chen DT, Lancaster JM.

Int J Cancer. 2016 Feb 1;138(3):612-9. doi: 10.1002/ijc.29799. Epub 2015 Aug 28.

11.

Prediction of Optimal Cytoreductive Surgery of Serous Ovarian Cancer With Gene Expression Data.

Abdallah R, Chon HS, Bou Zgheib N, Marchion DC, Wenham RM, Lancaster JM, Gonzalez-Bosquet J.

Int J Gynecol Cancer. 2015 Jul;25(6):1000-9. doi: 10.1097/IGC.0000000000000449.

PMID:
26098088
12.

BAD-mediated apoptotic pathway is associated with human cancer development.

Stickles XB, Marchion DC, Bicaku E, Al Sawah E, Abbasi F, Xiong Y, Bou Zgheib N, Boac BM, Orr BC, Judson PL, Berry A, Hakam A, Wenham RM, Apte SM, Berglund AE, Lancaster JM.

Int J Mol Med. 2015 Apr;35(4):1081-7. doi: 10.3892/ijmm.2015.2091. Epub 2015 Feb 5.

13.

Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.

Lancaster JM, Powell CB, Chen LM, Richardson DL; SGO Clinical Practice Committee.

Gynecol Oncol. 2015 Jan;136(1):3-7. doi: 10.1016/j.ygyno.2014.09.009. Epub 2014 Sep 17. Erratum in: Gynecol Oncol. 2015 Sep;138(3):765.

PMID:
25238946
14.

Metabolic vulnerabilities in endometrial cancer.

Byrne FL, Poon IK, Modesitt SC, Tomsig JL, Chow JD, Healy ME, Baker WD, Atkins KA, Lancaster JM, Marchion DC, Moley KH, Ravichandran KS, Slack-Davis JK, Hoehn KL.

Cancer Res. 2014 Oct 15;74(20):5832-45. doi: 10.1158/0008-5472.CAN-14-0254. Epub 2014 Sep 9.

15.

The Chinese herb polyphyllin D sensitizes ovarian cancer cells to cisplatin-induced growth arrest.

Al Sawah E, Marchion DC, Xiong Y, Ramirez IJ, Abbasi F, Boac BM, Bush SH, Bou Zgheib N, McClung EC, Khulpateea BR, Berry A, Hakam A, Wenham RM, Lancaster JM, Judson PL.

J Cancer Res Clin Oncol. 2015 Feb;141(2):237-42. doi: 10.1007/s00432-014-1797-x. Epub 2014 Aug 28.

PMID:
25164128
16.

Analysis of chemotherapeutic response in ovarian cancers using publicly available high-throughput data.

Bosquet JG, Marchion DC, Chon H, Lancaster JM, Chanock S.

Cancer Res. 2014 Jul 15;74(14):3902-12. doi: 10.1158/0008-5472.CAN-14-0186. Epub 2014 May 21.

17.

Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel.

Chen N, Chon HS, Xiong Y, Marchion DC, Judson PL, Hakam A, Gonzalez-Bosquet J, Permuth-Wey J, Wenham RM, Apte SM, Cheng JQ, Sellers TA, Lancaster JM.

Oncol Rep. 2014 Jan;31(1):376-83. doi: 10.3892/or.2013.2847. Epub 2013 Nov 13.

18.

Evidence of a chemopreventive effect of progestin unrelated to ovulation on reproductive tract cancers in the egg-laying hen.

Rodriguez GC, Barnes HJ, Anderson KE, Whitaker RS, Berchuck A, Petitte JN, Lancaster JM, Wenham RM, Turbov JM, Day R, Maxwell GL, Carver DK.

Cancer Prev Res (Phila). 2013 Dec;6(12):1283-92. doi: 10.1158/1940-6207.CAPR-12-0426. Epub 2013 Oct 17.

19.

Gene expression data reveal common pathways that characterize the unifocal nature of ovarian cancer.

Marchion DC, Xiong Y, Chon HS, Al Sawah E, Bou Zgheib N, Ramirez IJ, Abbasi F, Stickles XB, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund AE, Lancaster JM.

Am J Obstet Gynecol. 2013 Dec;209(6):576.e1-576.e16. doi: 10.1016/j.ajog.2013.08.004. Epub 2013 Aug 9.

20.

Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest.

Al Sawah E, Chen X, Marchion DC, Xiong Y, Ramirez IJ, Abbasi F, Bou Zgheib N, Chon HS, Wenham RM, Apte SM, Judson PL, Lancaster JM.

Gynecol Oncol. 2013 Oct;131(1):207-12. doi: 10.1016/j.ygyno.2013.07.088. Epub 2013 Jul 20.

PMID:
23877012
21.

A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy.

Wenham RM, Lapolla J, Lin HY, Apte SM, Lancaster JM, Judson PL, Gonzalez-Bosquet J, Herschberger A, Havrilesky LJ, Secord AA.

Gynecol Oncol. 2013 Jul;130(1):19-24. doi: 10.1016/j.ygyno.2013.04.049. Epub 2013 Apr 25.

PMID:
23623830
22.

Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.

Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin HY, Chen YA, Tsai YY, Qu X, Ramus SJ, Karevan R, Lee J, Lee N, Larson MC, Aben KK, Anton-Culver H, Antonenkova N, Antoniou AC, Armasu SM; Australian Cancer Study; Australian Ovarian Cancer Study, Bacot F, Baglietto L, Bandera EV, Barnholtz-Sloan J, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Cai Q, Campbell I, Chang-Claude J, Chanock S, Chenevix-Trench G, Cheng JQ, Cicek MS, Coetzee GA; Consortium of Investigators of Modifiers of BRCA1/2, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dörk T, du Bois A, Dürst M, Easton DF, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher DA, Flanagan JM, Garcia-Closas M, Gentry-Maharaj A, Giles GG, Glasspool RM, Gonzalez-Bosquet J, Goodman MT, Gore M, Górski B, Gronwald J, Hall P, Halle MK, Harter P, Heitz F, Hillemanns P, Hoatlin M, Høgdall CK, Høgdall E, Hosono S, Jakubowska A, Jensen A, Jim H, Kalli KR, Karlan BY, Kaye SB, Kelemen LE, Kiemeney LA, Kikkawa F, Konecny GE, Krakstad C, Kjaer SK, Kupryjanczyk J, Lambrechts D, Lambrechts S, Lancaster JM, Le ND, Leminen A, Levine DA, Liang D, Lim BK, Lin J, Lissowska J, Lu KH, Lubiński J, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson SH, Orlow I, Paul J, Pearce CL, Pejovic T, Pelttari LM, Pike MC, Poole EM, Raska P, Renner SP, Risch HA, Rodriguez-Rodriguez L, Rossing MA, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schwaab I, Severi G, Shridhar V, Shu XO, Shvetsov YB, Sieh W, Song H, Southey MC, Spiewankiewicz B, Stram D, Sutphen R, Teo SH, Terry KL, Tessier DC, Thompson PJ, Tworoger SS, van Altena AM, Vergote I, Vierkant RA, Vincent D, Vitonis AF, Wang-Gohrke S, Palmieri Weber R, Wentzensen N, Whittemore AS, Wik E, Wilkens LR, Winterhoff B, Woo YL, Wu AH, Xiang YB, Yang HP, Zheng W, Ziogas A, Zulkifli F, Phelan CM, Iversen E, Schildkraut JM, Berchuck A, Fridley BL, Goode EL, Pharoah PD, Monteiro AN, Sellers TA, Gayther SA.

Nat Commun. 2013;4:1627. doi: 10.1038/ncomms2613.

23.

Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers.

Teefey P, Bou Zgheib N, Apte SM, Gonzalez-Bosquet J, Judson PL, Roberts WS, Lancaster JM, Wenham RM.

Am J Obstet Gynecol. 2013 Jun;208(6):501.e1-7. doi: 10.1016/j.ajog.2013.03.012. Epub 2013 Mar 15.

PMID:
23507546
24.

A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.

Marchion DC, Bicaku E, Xiong Y, Bou Zgheib N, Al Sawah E, Stickles XB, Judson PL, Lopez AS, Cubitt CL, Gonzalez-Bosquet J, Wenham RM, Apte SM, Berglund A, Lancaster JM.

Oncol Rep. 2013 May;29(5):2011-8. doi: 10.3892/or.2013.2329. Epub 2013 Mar 5.

25.

Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers.

Pal T, Lee JH, Besharat A, Thompson Z, Monteiro AN, Phelan C, Lancaster JM, Metcalfe K, Sellers TA, Vadaparampil S, Narod SA.

Clin Genet. 2014 Jan;85(1):49-53. doi: 10.1111/cge.12130. Epub 2013 Mar 21.

26.

Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer.

Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J, Lancaster JM, Coppola D, Sellers TA, Djeu JY, Cheng JQ.

Oncogene. 2014 Feb 6;33(6):679-89. doi: 10.1038/onc.2012.636. Epub 2013 Jan 28.

27.

MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog.

Xu CX, Xu M, Tan L, Yang H, Permuth-Wey J, Kruk PA, Wenham RM, Nicosia SV, Lancaster JM, Sellers TA, Cheng JQ.

J Biol Chem. 2012 Oct 12;287(42):34970-8. doi: 10.1074/jbc.M112.374611. Epub 2012 Aug 27. Retraction in: J Biol Chem. 2016 Oct 21;291(43):22851.

28.

Characterizing the efficacy of fermented wheat germ extract against ovarian cancer and defining the genomic basis of its activity.

Judson PL, Al Sawah E, Marchion DC, Xiong Y, Bicaku E, Bou Zgheib N, Chon HS, Stickles XB, Hakam A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Chen DT, Lancaster JM.

Int J Gynecol Cancer. 2012 Jul;22(6):960-7. doi: 10.1097/IGC.0b013e318258509d.

29.

In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival.

Bicaku E, Xiong Y, Marchion DC, Chon HS, Stickles XB, Chen N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Fulp W, Cubitt CL, Chen DT, Lancaster JM.

Br J Cancer. 2012 Jun 5;106(12):1967-75. doi: 10.1038/bjc.2012.207. Epub 2012 May 17.

30.

The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer.

Bou Zgheib N, Xiong Y, Marchion DC, Bicaku E, Chon HS, Stickles XB, Sawah EA, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Cubitt CL, Chen DT, Lancaster JM.

Int J Oncol. 2012 Jul;41(1):179-88. doi: 10.3892/ijo.2012.1451. Epub 2012 Apr 26.

31.

BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin.

Bansal N, Marchion DC, Bicaku E, Xiong Y, Chen N, Stickles XB, Sawah EA, Wenham RM, Apte SM, Gonzalez-Bosquet J, Judson PL, Hakam A, Lancaster JM.

J Gynecol Oncol. 2012 Jan;23(1):35-42. doi: 10.3802/jgo.2012.23.1.35. Epub 2012 Jan 9.

32.

Preoperative enoxaparin is safe to use in major gynecologic surgery for prophylaxis of venous thromboembolism: a retrospective cohort study.

Martino MA, George JG, Chen CC, Galic V, Kapoor R, Murray KC, Shubella J, Riker E, Lancaster JM, Hoffman MS.

Int J Gynecol Cancer. 2012 May;22(4):681-5. doi: 10.1097/IGC.0b013e3182454499.

PMID:
22343972
33.

The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin.

Chon HS, Marchion DC, Xiong Y, Chen N, Bicaku E, Stickles XB, Bou Zgheib N, Judson PL, Hakam A, Gonzalez-Bosquet J, Wenham RM, Apte SM, Lancaster JM.

Gynecol Oncol. 2012 Jan;124(1):119-24. doi: 10.1016/j.ygyno.2011.09.020. Epub 2011 Oct 26.

PMID:
22032837
34.

Fascin protein is critical for transforming growth factor β protein-induced invasion and filopodia formation in spindle-shaped tumor cells.

Sun J, He H, Xiong Y, Lu S, Shen J, Cheng A, Chang WC, Hou MF, Lancaster JM, Kim M, Yang S.

J Biol Chem. 2011 Nov 11;286(45):38865-75. doi: 10.1074/jbc.M111.270413. Epub 2011 Sep 13.

35.

BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.

Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, Hakam A, Li L, Su D, Moreno C, Judson PL, Berchuck A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Bloom GC, Eschrich SA, Sebti S, Chen DT, Lancaster JM.

Clin Cancer Res. 2011 Oct 1;17(19):6356-66. doi: 10.1158/1078-0432.CCR-11-0735. Epub 2011 Aug 17.

36.

MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium.

Permuth-Wey J, Chen Z, Tsai YY, Lin HY, Chen YA, Barnholtz-Sloan J, Birrer MJ, Chanock SJ, Cramer DW, Cunningham JM, Fenstermacher D, Fridley BL, Garcia-Closas M, Gayther SA, Gentry-Maharaj A, Gonzalez-Bosquet J, Iversen E, Jim H, McLaughlin J, Menon U, Narod SA, Phelan CM, Ramus SJ, Risch H, Song H, Sutphen R, Terry KL, Tyrer J, Vierkant RA, Wentzensen N, Lancaster JM, Cheng JQ, Berchuck A, Pharoah PD, Schildkraut JM, Goode EL, Sellers TA; Ovarian Cancer Association Consortium (OCAC).

Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1793-7. doi: 10.1158/1055-9965.EPI-11-0397. Epub 2011 Jun 2.

37.

LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer.

Permuth-Wey J, Kim D, Tsai YY, Lin HY, Chen YA, Barnholtz-Sloan J, Birrer MJ, Bloom G, Chanock SJ, Chen Z, Cramer DW, Cunningham JM, Dagne G, Ebbert-Syfrett J, Fenstermacher D, Fridley BL, Garcia-Closas M, Gayther SA, Ge W, Gentry-Maharaj A, Gonzalez-Bosquet J, Goode EL, Iversen E, Jim H, Kong W, McLaughlin J, Menon U, Monteiro AN, Narod SA, Pharoah PD, Phelan CM, Qu X, Ramus SJ, Risch H, Schildkraut JM, Song H, Stockwell H, Sutphen R, Terry KL, Tyrer J, Vierkant RA, Wentzensen N, Lancaster JM, Cheng JQ, Sellers TA; Ovarian Cancer Association Consortium.

Cancer Res. 2011 Jun 1;71(11):3896-903. doi: 10.1158/0008-5472.CAN-10-4167. Epub 2011 Apr 11.

38.

Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk.

Permuth-Wey J, Chen YA, Tsai YY, Chen Z, Qu X, Lancaster JM, Stockwell H, Dagne G, Iversen E, Risch H, Barnholtz-Sloan J, Cunningham JM, Vierkant RA, Fridley BL, Sutphen R, McLaughlin J, Narod SA, Goode EL, Schildkraut JM, Fenstermacher D, Phelan CM, Sellers TA.

Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1131-45. doi: 10.1158/1055-9965.EPI-10-1224. Epub 2011 Mar 29.

39.

Microarray-based gene expression studies in ovarian cancer.

Chon HS, Lancaster JM.

Cancer Control. 2011 Jan;18(1):8-15. Review.

PMID:
21273975
40.

Genomic-directed targeted therapy increases endometrial cancer cell sensitivity to doxorubicin.

Indermaur MD, Xiong Y, Kamath SG, Boren T, Hakam A, Wenham RM, Apte SM, Lancaster JM.

Am J Obstet Gynecol. 2010 Aug;203(2):158.e1-40. doi: 10.1016/j.ajog.2010.02.003. Epub 2010 May 4.

PMID:
20444440
41.

Inherited determinants of ovarian cancer survival.

Goode EL, Maurer MJ, Sellers TA, Phelan CM, Kalli KR, Fridley BL, Vierkant RA, Armasu SM, White KL, Keeney GL, Cliby WA, Rider DN, Kelemen LE, Jones MB, Peethambaram PP, Lancaster JM, Olson JE, Schildkraut JM, Cunningham JM, Hartmann LC.

Clin Cancer Res. 2010 Feb 1;16(3):995-1007. doi: 10.1158/1078-0432.CCR-09-2553. Epub 2010 Jan 26.

42.

Gedunin, a novel natural substance, inhibits ovarian cancer cell proliferation.

Kamath SG, Chen N, Xiong Y, Wenham R, Apte S, Humphrey M, Cragun J, Lancaster JM.

Int J Gynecol Cancer. 2009 Dec;19(9):1564-9. doi: 10.1111/IGC.0b013e3181a83135.

PMID:
19955938
43.

Electrothermal bipolar coagulation decreases the rate of red blood cell transfusions for pelvic exenterations.

Bansal N, Roberts WS, Apte SM, Lancaster JM, Wenham RM.

J Surg Oncol. 2009 Nov 1;100(6):511-4. doi: 10.1002/jso.21372.

PMID:
19697350
44.

Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome.

Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, Levine DA, Boyd J, Alonso MA, Secord AA, Bernardini MQ, Barnett JC, Boren T, Murphy SK, Dressman HK, Marks JR, Lancaster JM.

Clin Cancer Res. 2009 Apr 1;15(7):2448-55. doi: 10.1158/1078-0432.CCR-08-2430. Epub 2009 Mar 24.

45.

MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy.

Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, Kamath SG, Chen DT, Dressman H, Lancaster JM.

Gynecol Oncol. 2009 May;113(2):249-55. doi: 10.1016/j.ygyno.2009.01.014. Epub 2009 Feb 23.

PMID:
19237188
46.

Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu.

Hakim AA, Barry CP, Barnes HJ, Anderson KE, Petitte J, Whitaker R, Lancaster JM, Wenham RM, Carver DK, Turbov J, Berchuck A, Kopelovich L, Rodriguez GC.

Cancer Prev Res (Phila). 2009 Feb;2(2):114-21. doi: 10.1158/1940-6207.CAPR-08-0065. Epub 2009 Jan 27. Erratum in: Cancer Prev Res (Phila Pa). 2009 Mar;2(3):283.

47.

Ovarian cancer. Clinical practice guidelines in oncology.

Morgan RJ Jr, Alvarez RD, Armstrong DK, Boston B, Chen LM, Copeland L, Fowler J, Gaffney DK, Gershenson D, Greer BE, Grigsby PW, Havrilesky LJ, Johnston C, Lancaster JM, Lele S, Matulonis U, O'Malley D, Ozols RF, Remmenga SW, Sabbatini P, Schink J, Teng N; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2008 Sep;6(8):766-94. No abstract available.

PMID:
18926089
48.

MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis.

Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z, Kamath S, Chen DT, Dressman H, Lancaster JM.

Gynecol Oncol. 2008 Aug;110(2):206-15. doi: 10.1016/j.ygyno.2008.03.023. Epub 2008 May 21.

PMID:
18499237
49.

Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.

Lancaster JM, Powell CB, Kauff ND, Cass I, Chen LM, Lu KH, Mutch DG, Berchuck A, Karlan BY, Herzog TJ; Society of Gynecologic Oncologists Education Committee.

Gynecol Oncol. 2007 Nov;107(2):159-62.

PMID:
17950381
50.

Defining practice patterns in gynecologic oncology to prevent pulmonary embolism and deep venous thrombosis.

Martino MA, Williamson E, Rajaram L, Lancaster JM, Hoffman MS, Maxwell GL, Clarke-Pearson DL.

Gynecol Oncol. 2007 Sep;106(3):439-45. Epub 2007 Jun 28.

PMID:
17599396

Supplemental Content

Loading ...
Support Center